DE69931112D1 - Chimäre Adenoviren - Google Patents

Chimäre Adenoviren

Info

Publication number
DE69931112D1
DE69931112D1 DE69931112T DE69931112T DE69931112D1 DE 69931112 D1 DE69931112 D1 DE 69931112D1 DE 69931112 T DE69931112 T DE 69931112T DE 69931112 T DE69931112 T DE 69931112T DE 69931112 D1 DE69931112 D1 DE 69931112D1
Authority
DE
Germany
Prior art keywords
adenoviruses
gene therapy
chimaeric
decreased
hybrid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69931112T
Other languages
English (en)
Other versions
DE69931112T2 (de
Inventor
Jans Havenga
Ronald Vogels
Abraham Bout
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Vaccines and Prevention BV
Original Assignee
Crucell Holand BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holand BV filed Critical Crucell Holand BV
Application granted granted Critical
Publication of DE69931112D1 publication Critical patent/DE69931112D1/de
Publication of DE69931112T2 publication Critical patent/DE69931112T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10344—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
DE69931112T 1998-07-08 1999-07-08 Chimäre Adenoviren Expired - Lifetime DE69931112T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98202297 1998-07-08
EP98202297 1998-07-08

Publications (2)

Publication Number Publication Date
DE69931112D1 true DE69931112D1 (de) 2006-06-08
DE69931112T2 DE69931112T2 (de) 2006-12-07

Family

ID=8233905

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69931112T Expired - Lifetime DE69931112T2 (de) 1998-07-08 1999-07-08 Chimäre Adenoviren

Country Status (10)

Country Link
US (3) US20030017138A1 (de)
EP (1) EP0978566B1 (de)
JP (1) JP4472178B2 (de)
AT (1) ATE325200T1 (de)
AU (1) AU765276B2 (de)
CA (1) CA2303477C (de)
DE (1) DE69931112T2 (de)
ES (1) ES2263250T3 (de)
NZ (1) NZ503018A (de)
WO (1) WO2000003029A2 (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69638058D1 (de) 1995-06-15 2009-11-26 Crucell Holland Bv Verpackungssysteme für humane rekombinante Adenoviren zur Gentherapie
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
WO2000052186A1 (en) * 1999-03-04 2000-09-08 Introgene B.V. Means and methods for fibroblast-like or macrophage-like cell transduction
US6869936B1 (en) 1999-03-04 2005-03-22 Crucell Holland B.V. Means and methods for fibroblast-like or macrophage-like cell transduction
US20050232900A1 (en) * 1999-05-18 2005-10-20 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
EP1067188A1 (de) * 1999-07-08 2001-01-10 Introgene B.V. Infektion mit chimärischen Adenoviren der Zellen die für den Adenoviren Serotyp 5 Coxsacki Adenoviren Rezeptor (CAR) negativ sind
DE19956763A1 (de) * 1999-11-25 2001-06-13 Guenter Cichon Rekombinante Adenoviren mit reduzierter Affinität zu humanen Erythrozyten zur Anwendung in der Gentherapie
US6867022B1 (en) 2000-01-21 2005-03-15 Regents Of The University Of Michigan Replication deficient adenovirus vectors and methods of making and using them
EP1191105A1 (de) * 2000-09-25 2002-03-27 Galapagos Genomics B.V. Gentransfervektoren mit einer Gewebsspezifität für T-Lymphozyten
EP1157999A1 (de) * 2000-05-24 2001-11-28 Introgene B.V. Verfahren und Mitteln zur Verbesserung der Haut-Transplantation mittels Genabgabe-Vehikel mit Tropismus für primären Fibroblasten, sowie andere Verwendungsmöglichkeiten für diesen
AU2001263689B2 (en) 2000-05-31 2007-03-22 University Of Saskatchewan Modified bovine adenovirus having altered tropism
US7754201B2 (en) * 2000-06-02 2010-07-13 GenPhar, Inc Method of vaccination through serotype rotation
CA2418977C (en) * 2000-08-10 2011-01-18 Crucell Holland B.V. Gene delivery vectors with cell type specificity for primary human chondrocytes
DE60138403D1 (de) 2000-09-26 2009-05-28 Crucell Holland Bv Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
EP1195440A1 (de) * 2000-10-06 2002-04-10 Introgene B.V. Genverabreichung-Vektoren für Stammzellen
AU2002211087A1 (en) * 2000-10-06 2002-04-15 Crucell Holland B.V. Gene delivery vectors for stem cells
AU2002314705A1 (en) * 2001-01-09 2002-10-28 Beverly L. Davidson Adenovirus serotype 30 (ad30) fiber protein and uses thereof
US6635466B2 (en) 2001-01-09 2003-10-21 University Of Iowa Research Foundation Adenovirus serotype 30 (Ad30)
WO2002068627A2 (en) 2001-02-23 2002-09-06 Novartis Ag Vector constucts
JP2002325573A (ja) * 2001-04-27 2002-11-12 Japan Science & Technology Corp ベクター
EP1256803A1 (de) 2001-05-07 2002-11-13 Crucell Holland B.V. Verfahren zur Identifizierung von antiviralen Verbindungen
ES2375557T3 (es) 2001-06-22 2012-03-02 The Trustees Of The University Of Pennsylvania Adenovirus recombinantes que comprenden prote�?nas de adenovirus de simios y usos de los mismos.
EP1944043A1 (de) * 2001-11-21 2008-07-16 The Trustees of the University of Pennsylvania Nukleinsäure- und Aminosäuresequenzen von Affen-Adenoviren, hergeleitete Vektoren und Verwendungsverfahren.
AU2002365366B2 (en) 2001-11-21 2007-05-10 The Trustees Of The University Of Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
AU2007201747B2 (en) * 2001-11-21 2010-06-03 The Trustees Of The University Of Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
EP1516055A4 (de) * 2002-01-24 2007-08-08 Scripps Research Inst Faserschaftmodifikationen für effizientes zielen
NZ534865A (en) 2002-04-25 2008-07-31 Crucell Holland Bv Stable adenoviral vectors and methods for propagation thereof
ATE447037T1 (de) 2002-04-25 2009-11-15 Crucell Holland Bv Mittel und verfahren zur herstellung von adenovirusvektoren
WO2004027073A1 (en) * 2002-09-20 2004-04-01 Crucell Holland B.V. Modified adenoviral vectors for use in vaccines and gene therapy
AU2003288273A1 (en) 2002-10-23 2004-05-13 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
US20080153083A1 (en) 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
WO2004055187A1 (en) 2002-12-17 2004-07-01 Crucell Holland B.V. Recombinant viral-based malaria vaccines
JP2007525166A (ja) * 2003-03-28 2007-09-06 ザ・スクリップス・リサーチ・インスティテュート 樹状細胞に対する感染性が増大したアデノウイルス粒子と、肝細胞に対する感染性が低下した粒子
WO2004111251A2 (en) * 2003-06-11 2004-12-23 The Scripps Research Institute Modified fiber proteins for efficient receptor binding
US7291498B2 (en) 2003-06-20 2007-11-06 The Trustees Of The University Of Pennsylvania Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
US7491508B2 (en) 2003-06-20 2009-02-17 The Trustees Of The University Of Pennsylvania Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
DE602005015332D1 (de) 2004-02-23 2009-08-20 Crucell Holland Bv Verfahren zur Reinigung von Viren
KR101169109B1 (ko) * 2004-05-26 2012-07-26 싸이오서스 테라퓨틱스 엘티디. 암 치료에 사용하기 위한 키메릭 아데노바이러스
CA2583843C (en) * 2004-10-13 2010-09-21 Crucell Holland B.V. Improved adenoviral vectors and uses thereof
CN101155915B (zh) 2005-04-11 2013-12-04 克鲁塞尔荷兰公司 利用超滤进行病毒纯化
AU2005337612A1 (en) * 2005-10-28 2007-05-03 David T. Curiel Conditionally replicating viruses and methods for cancer virotherapy
US20090110695A1 (en) * 2006-03-27 2009-04-30 Menzo Jans Emko Havenga Compositions Comprising a Recombinant Adenovirus and an Adjuvant
MX2011004292A (es) 2008-11-03 2011-05-31 Crucell Holland Bv Metodo para la produccion de vectores adenovirales.
CN102575233B (zh) 2009-10-15 2014-07-16 克鲁塞尔荷兰公司 从高细胞密度培养物纯化腺病毒的方法
DK2488636T3 (da) 2009-10-15 2014-06-23 Crucell Holland Bv Fremgangsmåde til oprensning af adenoviruspartikler fra kulturer med høj celledensitet
WO2012024351A2 (en) * 2010-08-16 2012-02-23 Salk Institute For Biological Studies Adenoviral assembly method
EP2618838A1 (de) 2010-09-20 2013-07-31 Crucell Holland B.V. Therapeutische impfung gegen aktive tuberkulose
AU2012343981B2 (en) 2011-11-28 2017-09-07 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
EP2855669B1 (de) 2012-05-29 2018-10-10 GenVec, Inc. Modifizierte serotyp-28-adenovirusvektoren
WO2014153204A1 (en) 2013-03-14 2014-09-25 Salk Institute For Biological Studies Oncolytic adenovirus compositions
AP2016009154A0 (en) 2013-09-19 2016-04-30 Crucell Holland Bv Improved adenovirus formulations
EP3372236A1 (de) 2013-10-25 2018-09-12 PsiOxus Therapeutics Limited Onkolytische adenoviren, die mit heterologen genen ausgestattet sind
AU2016256582B2 (en) 2015-04-30 2020-10-29 Akamis Bio Limited Oncolytic adenovirus encoding a B7 protein
US20170067028A1 (en) * 2015-05-15 2017-03-09 Douglas J. Ballon Radiolabeling of adeno associated virus
EA036412B1 (ru) 2015-10-06 2020-11-09 Янссен Вэксинс Энд Превеншн Б.В. Способ обеспечения защиты аденовируса от разрушения, вызванного взаимодействием с пластиком, и применение 2-гидроксипропил--циклодекстрина для защиты аденовируса
IL260027B (en) 2015-12-17 2022-07-01 Psioxus Therapeutics Ltd A group b adenovirus that encodes an anti-tcr–complex antibody or particle
AU2017222568B2 (en) 2016-02-23 2020-09-10 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
AU2017223589B2 (en) 2016-02-23 2023-08-03 Salk Institute For Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
EP3532082A4 (de) 2016-12-12 2020-08-26 Salk Institute for Biological Studies Auf tumoren gerichtete synthetische adenoviren und verwendungen davon
CA3060573A1 (en) 2017-04-21 2018-10-25 Baylor College Of Medicine Oncolytic virotherapy and immunotherapy
CA3064863A1 (en) 2017-05-26 2018-11-29 Epicentrx, Inc. Recombinant adenoviruses carrying transgenes
GB202013940D0 (en) 2020-09-04 2020-10-21 Synpromics Ltd Regulatory nucleic acid sequences
EP4225382A2 (de) 2020-10-07 2023-08-16 Asklepios Biopharmaceutical, Inc. Therapeutische adeno-assoziierte virusverabreichung von fkutin-verwandtem protein (fkrp) zur behandlung von dystroglycanopathie. erkrankungen mit gliedmassengürtel 21
EP4338727A1 (de) 2022-09-14 2024-03-20 Roquette Freres Adenovirus-formulierungen

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4593002A (en) * 1982-01-11 1986-06-03 Salk Institute Biotechnology/Industrial Associates, Inc. Viruses with recombinant surface proteins
US4487829A (en) * 1982-03-23 1984-12-11 Massachusetts Institute Of Technology Production and use of monoclonal antibodies against adenoviruses
US4589881A (en) * 1982-08-04 1986-05-20 La Jolla Cancer Research Foundation Polypeptide
US4578079A (en) * 1982-08-04 1986-03-25 La Jolla Cancer Research Foundation Tetrapeptide
US4792525A (en) * 1982-08-04 1988-12-20 La Jolla Cancer Research Foundation Tetrapeptide
US4517686A (en) * 1982-08-04 1985-05-21 La Jolla Cancer Research Foundation Polypeptide
US4797368A (en) * 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
FR2602790B1 (fr) 1986-08-13 1990-06-01 Transgene Sa Expression d'un antigene specifique de tumeur par un virus vecteur recombinant et utilisation de celui-ci pour le traitement preventif ou curatif de la tumeur correspondante
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US4956281A (en) * 1987-06-03 1990-09-11 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3
US5024939A (en) * 1987-07-09 1991-06-18 Genentech, Inc. Transient expression system for producing recombinant protein
US5585254A (en) * 1987-08-21 1996-12-17 University Of Colorado Foundation, Inc. Autonomous parvovirus gene delivery vehicles and expression vectors
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5204445A (en) * 1988-10-03 1993-04-20 The Scripps Research Institute Peptides and antibodies that inhibit integrin-ligand binding
US5096815A (en) * 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5198346A (en) * 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
ATE174514T1 (de) * 1989-01-23 1999-01-15 Chiron Corp Rekombinante zellen für therapien von infektionen und hyperprolieferative störungen und deren herstellung
US5223394A (en) * 1989-04-10 1993-06-29 Biogen, Inc. Recombinant dna molecule comprising lymphocyte function-associated antigen 3 phosphatidylinositol linkage signal sequence
CA2062795A1 (en) 1989-06-29 1990-12-30 Michael W. Fanger Bispecific reagents for aids therapy
US5240846A (en) * 1989-08-22 1993-08-31 The Regents Of The University Of Michigan Gene therapy vector for cystic fibrosis
US5332567A (en) * 1989-08-24 1994-07-26 Immunomedics Detection and treatment of infections with immunoconjugates
US5436146A (en) * 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
DE69032979T2 (de) 1989-10-20 1999-11-04 Medarex Inc Bispezifische heteroantikörper mit zweifachen effektorfunktionen
WO1991005805A1 (en) 1989-10-20 1991-05-02 Trustees Of Dartmouth College MONOCLONAL ANTIBODY SPECIFIC FOR IgA RECEPTOR
WO1991018088A1 (en) * 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
US5349053A (en) * 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
US5246921A (en) * 1990-06-26 1993-09-21 The Wistar Institute Of Anatomy And Biology Method for treating leukemias
GB2246779B (en) 1990-08-03 1994-08-17 Delta Biotechnology Ltd Tumour-associated protease inhibitors targeted to tumour cells
GB9101550D0 (en) 1991-01-24 1991-03-06 Mastico Robert A Antigen-presenting chimaeric protein
DE69233013T2 (de) 1991-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
FR2681786A1 (fr) 1991-09-27 1993-04-02 Centre Nat Rech Scient Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires.
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5521291A (en) * 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
IL103059A0 (en) 1991-09-30 1993-02-21 Boehringer Ingelheim Int Conjugates for introducing nucleic acid into higher eucaryotic cells
JPH073958B2 (ja) * 1992-01-31 1995-01-18 インターナショナル・ビジネス・マシーンズ・コーポレイション 終端回路
JPH08501686A (ja) 1992-09-25 1996-02-27 ローン−プーラン・ロレ・ソシエテ・アノニム 中枢神経系、特に脳における細胞への外来遺伝子の転移のためのアデノウィルスベクター
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
EP0957172B1 (de) 1992-11-18 2005-10-19 Arch Development Corporation Adenovirus-gelenkter Gen-Transfer zum Herz-und glatten vaskulären Muskel
GB9300686D0 (en) 1993-01-15 1993-03-03 Imp Cancer Res Tech Compounds for targeting
WO1994017832A1 (en) 1993-02-09 1994-08-18 The Scripps Research Institute Targeting and delivery of genes and antiviral agents into cells by the adenovirus penton
DE4311651A1 (de) 1993-04-08 1994-10-13 Boehringer Ingelheim Int Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen
ATE221575T1 (de) 1993-05-10 2002-08-15 Univ Michigan Gentransfer zu den pankreatischen epithelzellen
US5543328A (en) * 1993-08-13 1996-08-06 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins
US5631236A (en) * 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
EP0716711A1 (de) 1993-09-03 1996-06-19 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Vektor für leber-gentherapie
US5552311A (en) * 1993-09-14 1996-09-03 University Of Alabama At Birmingham Research Foundation Purine nucleoside phosphorylase gene therapy for human malignancy
US5534423A (en) * 1993-10-08 1996-07-09 Regents Of The University Of Michigan Methods of increasing rates of infection by directing motion of vectors
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
IT1271461B (it) 1993-12-01 1997-05-28 Menarini Ricerche Sud Spa Anticorpo monoclonale bispecifico anti-cd3/anti-egfr,processo per la produzione e suo uso.
US5443953A (en) * 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates
US5928944A (en) 1994-02-04 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method of adenoviral-medicated cell transfection
US6312699B1 (en) 1994-03-28 2001-11-06 Uab Research Foundation Ligands added to adenovirus fiber
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
US5560905A (en) * 1994-05-13 1996-10-01 The Proctor & Gamble Company Oral compositions
DE69520496T2 (de) 1994-05-13 2001-07-12 Chiron Corp Verfahren und zusammensetzungen als vehikel zur zielgerichtete einbringen von genen
US5571531A (en) 1994-05-18 1996-11-05 Mcmaster University Microparticle delivery system with a functionalized silicone bonded to the matrix
US5570975A (en) 1994-06-27 1996-11-05 Reinert, Sr.; Gary L. Metal foundation push-it and installation apparatus and method
FR2721943B1 (fr) 1994-06-29 1996-08-02 Rhone Poulenc Rorer Sa Adenovirus comprenant un gene codant pour une superoxyde dismutase
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5846782A (en) * 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
EP0779923A2 (de) 1994-09-09 1997-06-25 Neurocrine Biosciences, Inc. Rezeptoren des typ 3 interleukin 1
FR2724846B1 (fr) 1994-09-27 1996-12-20 Rhone Poulenc Rorer Sa Methode de traitement des cancers par regulation de l'activite des proteines ras
FR2725726B1 (fr) * 1994-10-17 1997-01-03 Centre Nat Rech Scient Vecteurs viraux et utilisation en therapie genique
EP0787200B1 (de) * 1994-10-28 2005-04-20 The Trustees Of The University Of Pennsylvania Rekombinanter adenovirus und methoden zu dessen verwendung
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
WO1996014837A1 (en) 1994-11-09 1996-05-23 Genetic Therapy, Inc. Gene therapy for hypercholesterolemia
US5824547A (en) 1994-11-29 1998-10-20 Takara Shuzo Co., Ltd. Method for production of transfected cells
FR2727867B1 (fr) 1994-12-13 1997-01-31 Rhone Poulenc Rorer Sa Transfert de genes dans les motoneurones medullaires au moyen de vecteurs adenoviraux
AUPN107195A0 (en) 1995-02-10 1995-03-09 Withers, Graham Rex Metal matrix forming method and apparatus
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
AU5703796A (en) 1995-05-10 1996-11-29 Introgene B.V. Improved retroviral vectors, especially suitable for gene th erapy
DE69638058D1 (de) * 1995-06-15 2009-11-26 Crucell Holland Bv Verpackungssysteme für humane rekombinante Adenoviren zur Gentherapie
US5622699A (en) * 1995-09-11 1997-04-22 La Jolla Cancer Research Foundation Method of identifying molecules that home to a selected organ in vivo
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
EA199800475A1 (ru) * 1995-11-28 1998-12-24 Дженвек, Инк. Векторы и способы для переноса генов в клетки
JP2001520511A (ja) 1995-12-08 2001-10-30 ザ ユーナヴァーサティ オブ アラバマ アト バーミングハム リサーチ ファンデーション 向標的性アデノウイルス・ベクター
WO1997038723A1 (en) 1996-04-16 1997-10-23 Immusol Incorporated Targeted viral vectors
US5877011A (en) * 1996-11-20 1999-03-02 Genzyme Corporation Chimeric adenoviral vectors
US5922315A (en) * 1997-01-24 1999-07-13 Genetic Therapy, Inc. Adenoviruses having altered hexon proteins
ATE296117T1 (de) * 1997-03-07 2005-06-15 Wistar Inst Verwendung von adenoviralen vektoren, die pdgf oder vegf exprimieren, zur heilung von gewebsdefekten und zur induzierung der hypervaskulität in säugergeweben
US6100086A (en) * 1997-04-14 2000-08-08 Genzyme Corporation Transgene expression systems
JP2002513290A (ja) * 1997-05-08 2002-05-08 ジェネティック・セラピー・インコーポレテッド 修飾されたファイバー蛋白質を有するアデノウイルスによる遺伝子移入
US5849561A (en) * 1997-05-22 1998-12-15 Cornell Research Foundation, Inc. Method for the production of non-group C adenoviral vectors
US6287857B1 (en) * 1998-02-09 2001-09-11 Genzyme Corporation Nucleic acid delivery vehicles
WO1999047180A1 (en) 1998-03-20 1999-09-23 Genzyme Corporation Chimeric adenoviral vectors for targeted gene delivery
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
EP1112372A1 (de) * 1998-09-11 2001-07-04 Genvec, Inc. Adenovirus mit veränderter zielzellenspezifität
EP1020529B1 (de) 1998-11-20 2005-06-01 Crucell Holland B.V. Genverabreichende Vektoren mit Gewebetropismus für glatte Muskelzellen und/oder Endothelzellen
EP1016726A1 (de) 1998-12-30 2000-07-05 Introgene B.V. Gentherapie zur Förderung der Angiogenesis
US6869936B1 (en) * 1999-03-04 2005-03-22 Crucell Holland B.V. Means and methods for fibroblast-like or macrophage-like cell transduction
PT1818408E (pt) 1999-05-17 2011-11-15 Crucell Holland Bv Adenovírus recombinante do serótipo ad11
US6492169B1 (en) * 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
EP1067188A1 (de) 1999-07-08 2001-01-10 Introgene B.V. Infektion mit chimärischen Adenoviren der Zellen die für den Adenoviren Serotyp 5 Coxsacki Adenoviren Rezeptor (CAR) negativ sind
EP1157999A1 (de) 2000-05-24 2001-11-28 Introgene B.V. Verfahren und Mitteln zur Verbesserung der Haut-Transplantation mittels Genabgabe-Vehikel mit Tropismus für primären Fibroblasten, sowie andere Verwendungsmöglichkeiten für diesen
CA2418977C (en) * 2000-08-10 2011-01-18 Crucell Holland B.V. Gene delivery vectors with cell type specificity for primary human chondrocytes
US6905678B2 (en) * 2001-07-07 2005-06-14 Crucell Holland B.V. Gene delivery vectors with cell type specificity for mesenchymal stem cells

Also Published As

Publication number Publication date
DE69931112T2 (de) 2006-12-07
EP0978566B1 (de) 2006-05-03
ATE325200T1 (de) 2006-06-15
AU765276B2 (en) 2003-09-11
WO2000003029A2 (en) 2000-01-20
JP4472178B2 (ja) 2010-06-02
CA2303477C (en) 2010-04-06
EP0978566A3 (de) 2000-04-19
AU4935699A (en) 2000-02-01
US7749493B2 (en) 2010-07-06
US20060014276A1 (en) 2006-01-19
NZ503018A (en) 2003-06-30
WO2000003029A3 (en) 2000-03-16
CA2303477A1 (en) 2000-01-20
EP0978566A2 (de) 2000-02-09
ES2263250T3 (es) 2006-12-01
US20030073072A1 (en) 2003-04-17
JP2002520026A (ja) 2002-07-09
US20030017138A1 (en) 2003-01-23

Similar Documents

Publication Publication Date Title
DE69931112D1 (de) Chimäre Adenoviren
Croyle et al. PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver
Cui et al. Rabbits immunized with Epstein-Barr virus gH/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350
HUP0101207A2 (hu) Rekombináns és adjuvánstartalmú élő oltóanyagok
Yang et al. Oral vaccination with Salmonella simultaneously expressing Yersinia pestis F1 and V antigens protects against bubonic and pneumonic plague
Welten et al. Fuel and brake of memory T cell inflation
MXPA01008966A (es) Vacunas contra el virus sincicial respiratorio a base de acido nucleico.
DE69734882D1 (de) Dna immunisierung gegen chlamydia infektion
Rüedi et al. Antiviral T cell competence and restriction specificity of mixed allogeneic (P1+ P2→ P1) irradiation chimeras
ATE395932T1 (de) Rekombinanter immunschwächepoxvirus
CA2131729A1 (en) Helicobacter pylori proteins useful for vaccines and diagnostics
CA2385655A1 (en) Dna immunization against chlamydia infection
Triozzi et al. Phase I study of a plasmid DNA vaccine encoding MART-1 in patients with resected melanoma at risk for relapse
Steffensen et al. Pre-existing vector immunity does not prevent replication deficient adenovirus from inducing efficient CD8 T-cell memory and recall responses
KR20220097440A (ko) 변형된 캡시드 단백질을 갖는 바이러스
Thomas et al. Dimerization of dengue virus E subunits impacts antibody function and domain focus
US20230321209A1 (en) Modified mycobacterium bovis vaccines
Bos et al. Cationic polymers that enhance the performance of HbsAg DNA in vivo
EP1266662A2 (de) Synthetische Peptide Impfstoffe für Zahnkaries
DK0892054T3 (da) Clostridium perfringens-vaccine
Choi et al. Bolstering components of the immune response compromised by prior exposure to adenovirus: guided formulation development for a nasal Ebola vaccine
DK0843731T3 (da) Adenovirusvektorer til genterapi
Ossevoort et al. Creation of immune ‘stealth’genes for gene therapy through fusion with the Gly-Ala repeat of EBNA-1
MX2022016287A (es) Secuencias de acidos nucleicos y de aminoacidos de adenovirus de gorila, vectores que contienen las mismas y usos de las mismas.
Babu et al. Priming for virus-specific CD8+ but not CD4+ cytotoxic T lymphocytes with synthetic lipopeptide is influenced by acylation units and liposome encapsulation

Legal Events

Date Code Title Description
8364 No opposition during term of opposition